History of us

More than 10 years in Genomics

2013

Initiation of Genetics Operations
in Yong-in city, Republic of Korea

2014

Newly launching of genomic analysis services.

  • Diagnostic Exome Sequencing (DES) Test
  • Type 1 Myotonic Dystrophy | ProtectMe® Women’s Cancer

2015

Launch of Drug Suitability DNA test
Obtained Grade A Accuracy Evaluation for Genetic Testing
Release of non-invasive prenatal screening test G-NIPT®

2016

Acquisition of patent for G-NIPT® proprietary algorithm
Release of newborn genomic screening test i-screen®

2017

Acquisition of NGS Clinical Laboratory Certification from the Ministry
of Food and Drug Safety (MFDS)
Obtained certification from the College of American Pathologists (CAP)

2018

The 1st Launch in Korea of NGS-based preventive screening test Genome Screen

2019

Release of Greenbiome® for gut microbiome testing
Patent registration for Liquid Biopsy Core Technology
Domestic launch of Guardant360 liquid biopsy test

2020

Relocation to [GC Cell center] Launch of Risk Screen test, a genetic test for identifying genetic factors associated with disease susceptibility
in health screenings.

2021

Launch of TelorisK®, a test for measuring aging speed
Expansion of testing facilities and establishment of Data centers.
Release of GreenPlan® HRD for assessing recombination deficiency.

2022

  • Patent registration for Detection Method and Use Thereof for Chromosomal Abnormalities
    based on Whole Genome Sequencing.
  • Designation of Clinical Trial Sample Analysis Facility (GCLP) by the Ministry of Food and Drug Safety
  • Approval of GreenPlan® HRD, the first domestically approved HRD advanced medical technology

2023

Expansion to Europe with G-NIPT® (Greece, Bulgaria, Serbia, North Makedonia)
New microbiome test, GreenBiome® Lady released